These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1503 related articles for article (PubMed ID: 32422178)
21. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662 [TBL] [Abstract][Full Text] [Related]
22. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Schijns V; Lavelle EC Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473 [TBL] [Abstract][Full Text] [Related]
23. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289 [TBL] [Abstract][Full Text] [Related]
24. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068 [TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV. Castel AD; Wilbourn B; Magnus M; Greenberg AE AIDS Rev; 2020; 22(3):133-142. PubMed ID: 33118529 [TBL] [Abstract][Full Text] [Related]
26. The use of nebulized pharmacotherapies during the COVID-19 pandemic. Sethi S; Barjaktarevic IZ; Tashkin DP Ther Adv Respir Dis; 2020; 14():1753466620954366. PubMed ID: 33167796 [TBL] [Abstract][Full Text] [Related]
27. A global treatments for coronaviruses including COVID-19. Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467 [TBL] [Abstract][Full Text] [Related]
28. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
29. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Jin M; Tong Q Emerg Infect Dis; 2020 Jul; 26(7):1618-1620. PubMed ID: 32197060 [TBL] [Abstract][Full Text] [Related]
30. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644 [TBL] [Abstract][Full Text] [Related]
31. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. Li YC; Bai WZ; Hashikawa T J Med Virol; 2020 Jun; 92(6):552-555. PubMed ID: 32104915 [TBL] [Abstract][Full Text] [Related]
32. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278 [TBL] [Abstract][Full Text] [Related]
33. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Sarzi-Puttini P; Giorgi V; Sirotti S; Marotto D; Ardizzone S; Rizzardini G; Antinori S; Galli M Clin Exp Rheumatol; 2020; 38(2):337-342. PubMed ID: 32202240 [TBL] [Abstract][Full Text] [Related]
34. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899 [TBL] [Abstract][Full Text] [Related]
35. Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome. Galassi G; Marchioni A Acta Neurol Belg; 2020 Oct; 120(5):1067-1075. PubMed ID: 32696312 [TBL] [Abstract][Full Text] [Related]
36. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967 [TBL] [Abstract][Full Text] [Related]
37. COVID-19: the epidemiology and treatment. Qu L; Li J; Ren H Br J Hosp Med (Lond); 2020 Oct; 81(10):1-9. PubMed ID: 33135928 [TBL] [Abstract][Full Text] [Related]
38. Antiviral therapy for coronavirus disease 2019. Gong S; Su J; Yan X; Li F; Hu L; Liu S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113 [TBL] [Abstract][Full Text] [Related]
39. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives. Turski WA; Wnorowski A; Turski GN; Turski CA; Turski L Restor Neurol Neurosci; 2020; 38(4):343-354. PubMed ID: 32597823 [TBL] [Abstract][Full Text] [Related]
40. Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2. Zhang H; Xie C; Huang Y J Thorac Oncol; 2020 May; 15(5):e63-e64. PubMed ID: 32147577 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]